|
| |
NiKem Research Srl Enters Into Research Service
Agreement with InterMune, Inc.
Milan, June 25th, 2007 -- NiKem Research Srl, an Italian drug discovery
service provider, announced today that it has entered into a Research Service
Agreement with InterMune, Inc., a California-based biotechnology company focused
on developing and commercializing innovative therapies in hepatology and
pulmonology. Under the terms of the agreement, NiKem will, in the next 12
months, use its medicinal chemistry and early ADMET/PK platform and expertise to
design, synthesize and profile drug-like compounds aimed towards specific,
undisclosed pulmonology targets of interest for InterMune. Financial terms of
the agreement were not disclosed.
By pursuing this business opportunity with InterMune, NiKem Research further
diversifies its client portfolio in Europe, the United States and Australia, now
comprising large pharmaceutical corporations, small biotechs and a number of
medium-sized companies.
Giuseppe Giardina, CEO of NiKem Research, said "Our integrated drug discovery
platform will be applied to important projects within InterMune’s pulmonology
research portfolio. We believe that our goal-oriented attitude, our
teamwork-driven working approach and our pragmatic way of thinking will be of
great value in this collaboration. Having noticed a similar mindset at InterMune
since the start of our discussions, we’re very pleased to initiate this
relationship among two leading companies in their respective areas.”
Pierfausto Seneci, CBO of NiKem Research, said, "We are delighted to start a
multi-FTE business relationship with InterMune. Our capacity to penetrate the US
market, notwithstanding the unfavourable €/$ exchange, is a strong proof of our
competitiveness as a worldwide provider of high quality services in drug
discovery. Our quality is assessed at best by the choice made by a respected
biotechnology company that is working to develop innovative therapies in areas
of unmet medical need, such as InterMune."
About NiKem Research
Based on decades of drug discovery experience and now operating at biotech
speed, NiKem Research offers a full range of drug discovery services to the
pharmaceutical industry. In addition to its expertise in medicinal chemistry
(hit validation, hit to lead and lead optimization, iterative and parallel
synthesis), NiKem Research provides its clients with computational and
analytical chemistry support, early ADMET services, biochemical screening and in
vivo DMPK. NiKem Research usually operates as a classical fee-for-service
partner, but other business relationships (i.e., project- or assay-based) are
also acceptable. For further information visit
www.nikemresearch.com
Media Contact:
NiKem Research Srl
Samadhi Battistoni
Tel. +39 02 35694 7429
Fax +39 02 35694 7606
Samadhi.battistoni@nikemresearch.com
| |
|
